Jennifer Walker

Dr. Jennifer Walker


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Autoimmunity Reviews
Verified
Journal Article
Closed access
SMSonal Mehra
Sonal Mehra
JWJennifer Walker
Jennifer Walker
KPKaren Patterson
Karen Patterson
MFMarvin J. Fritzler
Marvin J. Fritzler

1 February 2006 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JWJennifer Walker
Jennifer Walker
MAM J Ahern
M J Ahern
MCM Coleman
M Coleman
HWH Weedon
H Weedon
VPV Papangelis
V Papangelis
MSM D Smith
M D Smith
Background: Modulation of Jak-STAT signalling may provide an effective therapeutic strategy in inflammatory arthritis. Objective: To document Jak-STAT expression in a cohort of patients with active rheumatoid arthritis (RA), spondyloarthritis (SpA), and osteoarthritis (OA) and compare these subsets with normal synovial tissue. Methods: Synovial tissue biopsy specimens from patients with RA, OA, and SpA and histologically normal tissue (n = 10 in each arthritis group) were examined for the presence of Jak3, STAT1, STAT4, and STAT6 expression using immunohistochemistry. Phenotyping was performed using immunohistochemistry and immunofluorescence. Clinical and serological characteristics of patients with RA expressing Jak3-STAT4 were assessed. Results: STAT1, STAT4, and Jak3 protein expression was generally increased in inflammatory arthritis. In contrast, STAT6 expression was relatively heterogeneous. A subpopulation of CD1a positive dendritic cells unique to seropositive patients with RA was detected. These cells showed intense protein expression for Jak3, STAT4, and STAT6. Conclusion: CD1a positive dendritic cells intensely express Jak3, STAT4, and STAT6 in seropositive RA tissue and may be an alternative marker for dendritic cells in their early stages of activation as well as providing a tool for identifying RA at the level of the synovium. Jak3 inhibition may be a potential therapeutic target to prevent dendritic cell maturation in RA. STAT1 expression is increased in inflammatory arthritis, suggesting that its pro-apoptotic and anti-inflammatory effects cannot effectively counteract inflammation. STAT6 expression is heterogeneous in synovium, suggesting a possible homoeostatic role in addition to any anti-inflammatory effects.

18 January 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
YHYanjie Hao
Yanjie Hao
VTVivek Thakkar
Vivek Thakkar
WSWendy Stevens
Wendy Stevens
KMKathleen Morrisroe
Kathleen Morrisroe
DPDavid Prior
David Prior
MNMandana Nikpour
Mandana Nikpour
Introduction: There is evidence that early screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) improves outcomes. We compared the predictive accuracy of two recently published screening algorithms (DETECT 2013 and Australian Scleroderma Interest Group (ASIG) 2012) for SSc-associated PAH (SSc-PAH) with the commonly used European Society of Cardiology/European Respiratory Society (ESC/ERS 2009) guidelines. Methods: We included 73 consecutive SSc patients with suspected PAH undergoing right heart catheterization (RHC). The three screening models were applied to each patient. For each model, contingency table analysis was used to determine sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values for PAH. These properties were also evaluated in an ‘alternate scenario analysis’ in which the prevalence of PAH was set at 10%. Results: RHC revealed PAH in 27 (36.9%) patients. DETECT and ASIG algorithms performed equally in predicting PAH with sensitivity and NPV of 100%. The ESC/ERS guidelines had sensitivity of 96.3% and NPV of only 91%, missing one case of PAH; these guidelines could not be applied to three patients who had absent tricuspid regurgitant (TR) jet. The ASIG algorithm had the highest specificity (54.5%). With PAH prevalence set at 10%, the NPV of the models was unchanged, but the PPV dropped to less than 20%. Conclusions: In this cohort, the DETECT and ASIG algorithms out-perform the ESC/ERS guidelines, detecting all patients with PAH. The ESC/ERS guidelines have limitations in the absence of a TR jet. Ultimately, the choice of SSc-PAH screening algorithm will also depend on cost and ease of application.

5 August 2015 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
KPK. A. Patterson
K. A. Patterson
PRP. J. Roberts‐Thomson
P. J. Roberts‐Thomson
SLS. Lester
S. Lester
JTJ. A. Tan
J. A. Tan
PHP. Hakendorf
P. Hakendorf
JWJennifer Walker
Jennifer Walker
Objective: To determine the relationships between systemic sclerosis (SSc)–related autoantibodies, as well as their clinical associations, in a well‐characterized Australian patient cohort.Methods: Serum from 505 Australian SSc patients were analyzed with a commercial line immunoassay (EuroLine; Euroimmun) for autoantibodies to centromere proteins CENP‐A and CENP‐B, RNA polymerase III (RNAP III; epitopes 11 and 155), the 90‐kd nucleolar protein NOR‐90, fibrillarin, Th/To, PM/Scl‐75, PM/Scl‐100, Ku, topoisomerase I (topo I), tripartite motif–containing protein 21/Ro 52, and platelet‐derived growth factor receptor. Patient subgroups were identified by hierarchical clustering of the first 2 dimensions of a principal components analysis of quantitative autoantibody scores. Results were compared with detailed clinical data.Results: A total of 449 of the 505 patients were positive for at least 1 autoantibody by immunoblotting. Heatmap visualization of autoantibody scores, along with principal components analysis clustering, demonstrated strong, mutually exclusive relationships between CENP, RNAP III, and topo I. Five patient clusters were identified: CENP, RNAP III strong, RNAP III weak, topo I, and other. Clinical features associated with CENP, RNAP III, and topo I were consistent with previously published reports concerning limited cutaneous and diffuse cutaneous SSc. A novel finding was the statistical separation of RNAP III into 2 clusters. Patients in the RNAP III strong cluster had an increased risk of gastric antral vascular ectasia, but a lower risk of esophageal dysmotility. Patients in the other cluster were more likely to be male and to have a history of smoking and a history of malignancy, but were less likely to have telangiectasia, Raynaud's phenomenon, and joint contractures.Conclusion: Five major autoantibody clusters with specific clinical and serologic associations were identified in Australian SSc patients. Subclassification and disease stratification using autoantibodies may have clinical utility, particularly in early disease.

30 November 2011 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SGScott W. Graf
Scott W. Graf
PHPaul Hakendorf
Paul Hakendorf
SLSue Lester
Sue Lester
KPKaren Patterson
Karen Patterson
JWJennifer Walker
Jennifer Walker
PRPeter J. Roberts‐Thomson
Peter J. Roberts‐Thomson

20 May 2001 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
PRP. J. Roberts‐Thomson
P. J. Roberts‐Thomson
MJM. Jones
M. Jones
PHP. Hakendorf
P. Hakendorf
ADA. A. S. S. Kencana Dharmapatni
A. A. S. S. Kencana Dharmapatni
JWJennifer Walker
Jennifer Walker
MAM. J. Ahern
M. J. Ahern